FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome

Annexon Biosciences has secured fast track designation from the US Food and Drug Administration (FDA) for its novel C1q inhibitor, ANX005, to treat Guillain-Barré Syndrome (GBS).